Request Deal Involvement

Sequoia China led the $150m Series B round in VISEN Pharmaceuticals.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Principals

VISEN PHARMACEUTICALS

target

VISEN PHARMACEUTICALS

ORBIMED PE

bidder

ORBIMED PE

SHERPA HEALTHCARE PARTNERS

bidder

SHERPA HEALTHCARE PARTNERS

CORMORANT ASSET MANAGEMENT

bidder

CORMORANT ASSET MANAGEMENT

HBM HEALTHCARE INVESTMENTS

bidder

HBM HEALTHCARE INVESTMENTS

PIVOTAL BIOVENTURE PARTNERS LLC

bidder

PIVOTAL BIOVENTURE PARTNERS LLC

LOGOS CAPITAL

bidder

LOGOS CAPITAL

CDG GROUP LLC

bidder

CDG GROUP LLC

ASCENDIS PHARMA AS

bidder

ASCENDIS PHARMA AS

VIVO CAPITAL LLC

bidder

VIVO CAPITAL LLC

SOFINNOVA PARTNERS

bidder

SOFINNOVA PARTNERS

HONGSHAN (EX-SEQUOIA CAPITAL CHINA)

bidder

HONGSHAN (EX-SEQUOIA CAPITAL CHINA)

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Sequoia China led the $150m Series B round in VISEN Pharmaceuticals.